Analyst Ratings for [RCKT] Rocket Pharmaceuticals, Inc.

3/12/25	Initiated	Outperform	X
RCKT Rocket Pharmaceuticals BMO Capital Markets
$50
12/30/24	Initiated	Outperform	X
RCKT Rocket Pharmaceuticals Wedbush
$32
10/16/24	Initiated	Sector Outperform	X
RCKT Rocket Pharmaceuticals Scotiabank
4/2/24	Initiated	Neutral	X
RCKT Rocket Pharmaceuticals Goldman
$39
10/24/23	Initiated	Overweight	X
RCKT Rocket Pharmaceuticals Cantor Fitzgerald
$65
2/1/23	Initiated	Overweight	X
RCKT Rocket Pharmaceuticals Morgan Stanley
$45
11/8/22	Initiated	Buy	X
RCKT Rocket Pharmaceuticals Canaccord Genuity
$53
11/1/22	Initiated	Buy	X
RCKT Rocket Pharmaceuticals BTIG Research
$35
7/8/22	Initiated	Outperform	X
RCKT Rocket Pharmaceuticals Raymond James
$22
10/20/21	Resumed	Outperform	X
RCKT Rocket Pharmaceuticals Cowen
3/2/21	Initiated	Buy	X
RCKT Rocket Pharmaceuticals Stifel
$64
2/18/21	Initiated	Buy	X
RCKT Rocket Pharmaceuticals Needham
$75
4/23/19	Initiated	Outperform	X
RCKT Rocket Pharmaceuticals Robert W. Baird
3/15/19	Initiated	Buy	X
RCKT Rocket Pharmaceuticals BofA/Merrill
$27
2/5/19	Initiated	Outperform	X
RCKT Rocket Pharmaceuticals Oppenheimer
$39
9/13/18	Initiated	Buy	X
RCKT Rocket Pharmaceuticals Ladenburg Thalmann
$30
7/10/18	Initiated	Outperform	X
RCKT Rocket Pharmaceuticals William Blair
1/30/18	Initiated	Outperform	X
RCKT Rocket Pharmaceuticals Evercore ISI
$27

RCKT Rocket Pharmaceuticals, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.